This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-09. Anything still debated is marked as such rather than presented as settled.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
From 1933 onwards, poet Victor Neuburg edited a section called "The Poet's Corner" in a British newspaper, the Sunday Referee. Here he encouraged new talent by awarding weekly prizes. One prize went to the then-unknown Thomas, and the publisher of the Sunday Referee sponsored and Neuburg arranged for the publication of Thomas's first book, 18 Poems, in December 1934. The anthology was published by Fortune Press, in part a vanity publisher that did not pay its writers and expected them to buy a certain number of copies themselves. 18 Poems was noted for its visionary qualities which led to critic Desmond Hawkins writing that the work was "the sort of bomb that bursts no more than once in three years". The volume was critically acclaimed, netting him new admirers from the London poetry world, including Edith Sitwell and Edwin Muir. When "Light breaks where no sun shines" appeared in The Listener in 1934, it caught the attention of three senior figures in literary London, T. S. Eliot, Geoffrey Grigson and Stephen Spender. In December 1935, Thomas contributed the poem "The Hand That Signed the Paper" to Issue 18 of the bi-monthly New Verse. In 1936, his next collection Twenty-five Poems, published by J. M. Dent, also received much critical praise. Two years later, in 1938, Thomas won the Oscar Blumenthal Prize for Poetry; it was also the year in which New Directions offered to be his publisher in the United States. In all, he wrote half his poems while living at Cwmdonkin Drive before moving to London. During this time Thomas's reputation for heavy drinking developed.
Powstanie Wielkopolskie, [in:] J.Pajewski, Odbudowa państwa polskiego 1914–1918, Warszawa 1985, Janusz Pajewski, Znaczenia Powstania Wielkopolskiego dla odbudowy Państwa Polskiego w 1918 r., Zeszyty Naukowe UAM, Historia 1970, t.10 S. Rybka, Zerwane pęta. Wspomnienia z dni rewolucji niemieckiej i powstania polskiego 1918-1919, Poznań 1919 A. Rzepecki, Powstanie grudniowe w Wielkopolsce. 27 XII 1918, Poznań 1919 Z. Wieliczka, Wielkopolska w Prusy w dobie powstania 1918/1919, Poznań 1932 Z. Wroniak, Paderewski w Poznaniu, Kronika Miasta Poznania 1959, nr 4 H. Zieliński, Rola powstania wielkopolskiego oraz powstań śląskich w walce o zjednoczenie ziem zachodnich z Polską; (1918–1921), [in:] Droga przez Półwiecze. Dietrich Vogt: Der großpolnische Aufstand 1918/1919: Bericht, Erinnerungen, Dokumente. Marburg 1980 (J.-G.-Herder-Institut) ISBN 3-87969-147-9 Richard Blanke, Orphans of Versailles. The Germans in Western Poland 1918–1939, Lexington, KY., 1993 (presents somehow pro-German vision of the events)
==== Zonal necrosis ==== This is the most common type of drug-induced liver cell necrosis where the injury is largely confined to a particular zone of the liver lobule. It may manifest as a very high level of ALT and severe disturbance of liver function leading to acute liver failure.
This description highlights the partial double bond that exists between the carbonyl carbon and nitrogen, which raises the rotational barrier. Thus, the molecule is not able to freely rotate around its main axis and the (E)-configuration is preferred due to steric repulsion of the larger substituents. This molecule has been tentatively identified in interstellar space by the ALMA radio telescope. It may have formed on dust grains. This could prove to be a key molecule for interstellar pre-biotic chemistry due to its peptide bond.
Because PCR amplifies the regions of DNA that it targets, PCR can be used to analyze extremely small amounts of sample. This is often critical for forensic analysis, when only a trace amount of DNA is available as evidence. PCR may also be used in the analysis of ancient DNA that is tens of thousands of years old. These PCR-based techniques have been successfully used on animals, such as a forty-thousand-year-old mammoth, and also on human DNA, in applications ranging from the analysis of Egyptian mummies to the identification of a Russian tsar and the body of English king Richard III. Quantitative PCR or real-time PCR (qPCR not to be confused with RT-PCR) methods allow the estimation of the amount of a given sequence present in a sample—a technique often applied to quantitatively determine levels of gene expression. The MIQE guidelines written by professors Stephen Bustin, Michael Pfaffl, Mikael Kubista and colleagues outline how qPCR experiments shall be performed and the results reported. Quantitative PCR is an established tool for DNA quantification that measures the accumulation of DNA product after each round of PCR amplification. qPCR allows the quantification and detection of a specific DNA sequence in real time since it measures concentration while the synthesis process is taking place. There are two methods for simultaneous detection and quantification. The first method consists of using fluorescent dyes that are retained nonspecifically in between the double strands.
Sources: en.wikipedia.org
Once all the eggs are secured in the nest, the pair will spawn again. If more than one female is present in the breeding tank, the male may spawn with all of them. The spawning sessions will continue for two to four hours, and produce between 300 and 800 eggs. Dwarf gouramis have a fecundity of about 600 eggs.[1] Upon completion, the male will place a fine layer of bubbles beneath the eggs, assuring that they remain in the bubble nest. The male will protect the eggs and fry. In 12 to 24 hours the fry will hatch, and continue developing within the protection of the bubble nest. After three days they are sufficiently developed to be free swimming and leave the nest. When the fry are two to three days old the male should also be removed or he may consume the young. After spawning the female should be moved to a different tank. The male will now take sole responsibility for the eggs, aggressively defending the nest and surrounding territory. When first hatched, the tiny fry should be fed infusoria, and later, brine shrimp and finely ground flakes. Freeze-dried tablets may also be fed to older fry.
This new process led to an increase in output and profit for the company. Under Eli's supervision, the design for Building 22, a new five-floor plant that opened in Indianapolis in 1926, implemented the straight-line concept to improve production efficiency and lower production costs. One historian noted, "It was probably the most sophisticated production system in the American pharmaceutical industry." This more efficient manufacturing process also allowed the company to hire a regular workforce. Instead of recalling workers at peak times and laying them off when production demand fell, Lilly's regular workforce produced less-costly medicines in off-peak times using the same manufacturing facilities. During the 1920s, the introduction of new products brought the company financial success. In 1921, three University of Toronto scientists, John Macleod, Frederick Banting, and Charles Best, were working on the development of insulin for treatment of diabetes. Clowes proposed a collaboration with the researchers in December 1921, and then again March and May 1922. The researchers were hesitant to work with a commercial drug firm, particularly since they had the Connaught Laboratories' non-commercial facilities at hand. But as limits were reached at the scale to which Connaught could produce insulin, Clowes and Eli Lilly met with the researchers in 1922 to negotiate an agreement with the University of Toronto scientists to mass-produce insulin. The collaboration greatly accelerated the large-scale production of the extract.
=== Phase 1/2 === ABS-201 – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody Finasteride (IVL-3001, IVL-3002) – long-acting injection – alopecia – 5α-reductase inhibitor Finasteride (DA-4001, DA-4001C) – topical – alopecia – 5α-reductase inhibitor IMG-007 (HMPL-A28) – intravenous injection – alopecia areata – OX40 receptor antagonist
The body hair of surgical patients is often removed beforehand on the skin surrounding surgical sites. Shaving was the primary form of hair removal until reports in 1983 showed that it may lead to an increased risk of infection. Clippers are now the recommended pre-surgical hair removal method. A 2021 systematic review brought together evidence on different techniques for hair removal before surgery. This involved 25 studies with a total of 8919 participants. Using a razor probably increases the chance of developing a surgical site infection compared to using clippers or hair removal cream or not removing hair before surgery. Removing hair on the day of surgery rather than the day before may also slightly reduce the number of infections. Some people with trichiasis find it medically necessary to remove ingrown eyelashes. The shaving of hair has sometimes been used in attempts to eradicate lice or to minimize body odor due to the accumulation of odor-causing micro-organisms in hair. In extreme situations, people may need to remove all body hair to prevent or combat infestation by lice, fleas and other parasites. Such a practice was used, for example, in Ancient Egypt. It has been suggested that an increasing percentage of humans removing their pubic hair has led to reduced crab louse populations in some parts of the world.
The Mediterranean seeps appear to represent a rich habitat characterized by megafauna species richness (e.g., gastropods) or the exceptional size of some species such as sponges (Rhizaxinella pyrifera) and crabs (Chaceon mediterraneus), compared with their background counterparts. This contrasts with the low macro- and mega-faunal abundance and diversity of the deep eastern Mediterranean. Seep communities in the Mediterranean that include endemic chemosynthetic species and associated fauna differ from the other known seep communities in the world at the species level but also by the absence of the large-size bivalve genera Calyptogena or Bathymodiolus. The isolation of the Mediterranean seeps from the Atlantic Ocean after the Messinian crisis led to the development of unique communities, which are likely to differ in composition and structure from those in the Atlantic Ocean. Further expeditions involved quantitative sampling of habitats in different areas, from the Mediterranean Ridge to the eastern Nile deep-sea fan. Cold seeps discovered in the Sea of Marmara in 2008 have also revealed chemosynthesis-based communities that showed a considerable similarity to the symbiont-bearing fauna of eastern Mediterranean cold seeps.
Sources: en.wikipedia.org
High-vacuum systems generally require metal chambers with metal gasket seals such as Klein flanges or ISO flanges, rather than the rubber gaskets more common in low vacuum chamber seals. The system must be clean and free of organic matter to minimize outgassing. All materials, solid or liquid, have a small vapour pressure, and their outgassing becomes important when the vacuum pressure falls below this vapour pressure. As a result, many materials that work well in low vacuums, such as epoxy, will become a source of outgassing at higher vacuums. With these standard precautions, vacuums of 1 mPa are easily achieved with an assortment of molecular pumps. With careful design and operation, 1 μPa is possible. Several types of pumps may be used in sequence or in parallel. In a typical pumpdown sequence, a positive displacement pump would be used to remove most of the gas from a chamber, starting from atmosphere (760 Torr, 101 kPa) to 25 Torr (3 kPa). Then a sorption pump would be used to bring the pressure down to 10−4 Torr (10 mPa). A cryopump or turbomolecular pump would be used to bring the pressure further down to 10−8 Torr (1 μPa). An additional ion pump can be started below 10−6 Torr to remove gases which are not adequately handled by a cryopump or turbo pump, such as helium or hydrogen. Ultra-high vacuum generally requires custom-built equipment, strict operational procedures, and a fair amount of trial-and-error. Ultra-high vacuum systems are usually made of stainless steel with metal-gasketed vacuum flanges.
=== Type 1 diabetes === Type 1 diabetes mellitus, also known as insulin-dependent diabetes, is believed to be caused by an auto-immune mediated destruction of the insulin-producing beta cells in the body. The process of beta-cell destruction begins with insulitis activating antigen-presenting cells (APCs). APCs then trigger activation of CD4+ helper-T cells and chemokines/cytokines release. Then, the cytokines activate CD8+ cytotoxic–T cells which leads to beta-cell destruction. The destruction of these cells reduces the body's ability to respond to glucose levels in the body, therefore making it nearly impossible to properly regulate glucose and glucagon levels in the bloodstream. The body destroys 70–80% of beta cells, leaving only 20–30% of functioning cells. This can cause the patient to experience hyperglycemia, which leads to other adverse short-term and long-term conditions. The symptoms of diabetes can potentially be controlled with methods such as regular doses of insulin and sustaining a proper diet. However, these methods can be tedious and cumbersome to continuously perform on a daily basis.
The absence of the enzyme has no negative effect on growth and the bacteria show no phenotypeic differences, with the exception that lactobacillic acid or other cyclopropanoic acids do not occur among the fatty acids present. A similar experiment was carried out with artificially produced mutants of Brucella abortus. The bacteria are still able to multiply in macrophages, so lactobacillic acid has no effect on the intracellular life cycle. However, if the bacteria are cultivated in a culture medium with a low pH value and high osmolarity, less growth can be observed compared to the unmodified cells. These conditions can be transferred to the survival of B. abortus in the environment, where an acidic environment with high osmolarity can also occur. The mutants that do not produce lactobacillic acid have poorer chances of survival there and consequently cannot be transferred to a host as easily as is the case with a smear infection, for example. The study of the promoter of the cfa gene also shows that expression is promoted by low pH and high osmolarity, i.e. the enzyme CFA synthase is formed under these conditions. From the point of view of energy metabolism, the formation of the cyclopropane ring in lactobacillic acid means a relatively high energy expenditure for the cell. The S adenosylmethionine, which acts as a carrier of the methylene group, must then be regenerated from S adenosylhomocysteine. This is associated with the hydrolytic cleavage of three ATP molecules per molecule.
At the highest trophic level is typically an apex predator, a consumer with no natural predators in the food chain model. When any trophic level dies, detritivores and decomposers consume their organic material for energy and expel nutrients into the environment in their waste. Decomposers and detritivores break down the organic compounds into simple nutrients that are returned to the soil. These are the simple nutrients that plants require to create organic compounds. It is estimated that there are more than 100,000 different decomposers in existence. Models of trophic levels also often model energy transfer between trophic levels. Primary consumers get energy from the producer and pass it to the secondary and tertiary consumers.
=== Molecular structure of Cu(II)-histidine and ATCUN Motif === Sarkar solved the structure of the copper(II)-histidine molecule used for the treatment of Menkes disease. He discovered the ATCUN (Amino terminal Cu(II), Ni(II) binding) motif of proteins and peptides.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.